Photon-Enhanced AI Platforms for Multimodal Therapeutics

This study presents a next-generation computational pharmacology architecture: Photon-Enhanced AI Platforms for Multimodal Therapeutics (PEAI-MT). Unlike conventional therapeutic design frameworks, which typically rely on linear screening and fixed chemical parameters, PEAI-MT leverages multi-spectral photonic control integrated with adaptive artificial intelligence algorithms to enable real-time co-design of molecular, photonic, and nanotechnological therapeutic strategies. The platform operates by dynamically modulating photon wavelengths and intensities to precisely influence molecular interactions, binding dynamics, and energy landscapes. This allows the creation of hybrid treatment modalities—for example, combining chemotherapy with phototherapy and nanotechnology—designed specifically for each biological target. By treating light not as a passive accelerator but as an active design variable, PEAI-MT achieves significantly higher molecular precision, reduces computational costs, and accelerates therapeutic development cycles. Early computational evaluations indicate that spectral adaptation improves energy mapping fidelity and enhances therapeutic specificity. This paradigm shift establishes the foundation for autonomous, intelligent, and light-driven therapeutic engineering, paving the way for next-generation treatments that are personalized, adaptive, and multimodal.